How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,083 results for

Depo Provera

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Efficacy of Repetitive Transcranial Magnetic Stimulation for Improvement of Memory in Older Adults With TBI

methods of birth control: abstinence, oral contraceptive, Norplant, Depo-Provera, a condom with spermicide, a cervical cap with spermicide, a diaphragm with spermicide, an intrauterine device, surgical sterilization (having your tubes tied) Able to read, verbalize understanding, and voluntarily sign the Informed Consent Form prior to participating in any study-specific procedures or assessments Individuals who meet the study criteria but have impaired decision making capacity may participate provided

2018 Clinical Trials

122. Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI

by the investigator or designee). A highly effective form of birth control includes true sexual abstinence, a vasectomized sexual partner, Implanon®, female sterilization by tubal occlusion, any effective intrauterine device (IUD)/levonorgestrel intrauterine system (IUS), Depo-Provera (trademark) injections, oral contraceptive and Erva Patch (trademark) or Nuvaring (trademark) Women of childbearing potential (after menarche) must agree to use a highly effective form of birth control, as defined above, from

2018 Clinical Trials

123. Efficacy and Safety of SYN-010 in IBS-C

of study drug if the patient is a sexually active female of child-bearing potential (defined as any female who has experienced menarche and who is NOT permanently sterile or postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause). Adequate contraceptive measures include: oral contraceptives (stable use for two or more cycles before Screening); intrauterine device; Depo-Provera®; Norplant® System implants; partner with a vasectomy; double

2018 Clinical Trials

124. Suvorexant (Belsomra) for the Treatment of Bipolar Depression With Insomnia

by the MINI. Pregnant women or women of child bearing potential who are not using a medically accepted means of contraception (e.g. oral contraceptives, intrauterine device, barrier methods, or total abstinence from intercourse; Depo Provera is acceptable if it is started 3 months prior to enrollment). Patients who are a serious suicide or homicide risk, suicidal exclusion criteria as follows: Suicidal ideation associated with actual intent and a method or plan in the past year: "Yes" answers on items 4

2018 Clinical Trials

125. Cardiac Disease and Pregnancy

of irregular bleeding. Progestogen-only injectable (depot) injections of hormone (Depo-Provera®) These are intramuscular injections of progestogen which last for 12 weeks. Periods will often disappear, although they may be irregular or heavy for a while when you decide to stop the injections. The failure rate is low: only one pregnancy in 300 women per year. Injections might be a problem if you are on warfarin or have a needle phobia. Implant of progestogen (or Nexplanon®) This is a small implant which

2011 Royal College of Obstetricians and Gynaecologists

126. Management of Sickle Cell Disease in Pregnancy

of Sexual & Reproductive Healthcare guidance on postnatal hormonal contraception. 75 Contraceptive advice will often be the responsibility of primary care. Progestogen-containing contraceptives such as the progesterone only pill (Cerazette®, Organon Laboratories Ltd, Hoddesdon, UK), injectable contraceptives (Depo-Provera®, Pfizer Ltd, New York, USA) and the levenorgestrel intrauterine system (Mirena®, Bayer Schering Pharma AG, Berlin, Germany) are safe and effective in SCD. Estrogen-containing (...) contraceptives should be used as second-line agents. Barrier methods are as safe and effective in women with SCD as in the general population. There is only limited safety evidence on hormonal contraception in SCD; a Cochrane review 76 identified one randomised trial which showed that women taking intramuscular depo-medroxyprogesterone acetate (DMPA) were less likely to have a painful episode. 77 Evidence level 1- A systematic review analysing randomised and non-randomised studies demonstrated progestogens

2011 Royal College of Obstetricians and Gynaecologists

128. Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer

between days 21-24. Procedure: Hysterectomy Undergo hysterectomy Other: Laboratory Biomarker Analysis Correlative studies Drug: Medroxyprogesterone Acetate Given IM Other Names: Amen Aragest Ciclotal Clinofem Clinovir Cycrin Depo-Clinovir Depo-Provera Depot-Medroxyprogestereone Acetate Farlutal G-Farlutal Gestapuran Hysron Lutoral Medroxyprogesterone 17-Acetate Medroxyprogesteroni Acetas Methylacetoxyprogesterone Metipregnone MPA Nadigest Nadigest (vet) Nidaxin Nidaxin (vet) Oragest Perlutex Prodasone (...) Aragest Ciclotal Clinofem Clinovir Cycrin Depo-Clinovir Depo-Provera Depot-Medroxyprogestereone Acetate Farlutal G-Farlutal Gestapuran Hysron Lutoral Medroxyprogesterone 17-Acetate Medroxyprogesteroni Acetas Methylacetoxyprogesterone Metipregnone MPA Nadigest Nadigest (vet) Nidaxin Nidaxin (vet) Oragest Perlutex Prodasone Provera Sodelut G Veramix Outcome Measures Go to Primary Outcome Measures : Mean post-treatment tumor progesterone receptor score [ Time Frame: Up to 3 years ] The percent cells

2017 Clinical Trials

129. Impact of Liraglutide 3.0 on Body Fat Distribution

product(s) or related product(s). Known or suspected abuse of alcohol or narcotics. Language barrier, mental incapacity, unwillingness or inability to understand. Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods. These include abstinence and the following methods: diaphragm with spermacide, condom with spermacide (by male partner), intrauterine device, sponge, spermacide, Norplant®, Depo-Provera® or oral

2017 Clinical Trials

130. Post-Prandial Liver Glucose Metabolism in PCOS

. For non-PCOS groups: regular menstrual cycles at least 1.5 years after menarche, and no clinical evidence of hyperandrogenism. Exclusion Criteria: Use of medications known to affect insulin sensitivity: oral glucocorticoids within 10 days, atypical antipsychotics, immunosuppressant agents, HIV medications. Nexplanon, Depo-Provera or Mirena progesterone only contraceptives. Dermal patch or vaginal ring contraception methods. For controls only: metformin or oral contraception. Currently pregnant

2017 Clinical Trials

131. WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer

), tubal ligation, combined oral, transdermal or intra-vaginal hormonal contraceptives, medroxyprogesterone injections (e.g. Depo-Provera), copper-banded intra-uterine devices; hormone impregnated intra-uterine systems and vasectomised partners. All methods of contraception (with the exception of total abstinence) should be used in combination with the use of a condom by their male sexual partner for intercourse. Inclusion criteria Group A - in addition to general criteria Accessible tumours for re

2017 Clinical Trials

132. A Pilot Study of Fear Extinction Learning in Anxious Youth

the previous 2 years (at least 10 treatment sessions over a period of less than 1 year conducted by a licensed provider of CBT) Child has a major neurological disorder, a major medical illness or hearing impairment that requires a prohibited episodic or chronic systemic medication or that would interfere Child is pregnant as indicated by history or a positive pregnancy test at Gate B. Sexually active girls must agree to use an effective form of birth control, either hormonal (BCP, Depo-Provera or Norplant

2017 Clinical Trials

133. The Effect of a High Protein, High Fiber Dietary Supplement on Weight and Fat Loss

), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) for at least 3 months Double-barrier method Non-hormonal IUDs Hormonal IUD methods must be a stable dose for at least 3 months Vasectomy of partner Non-heterosexual lifestyle A BMI between 27.0 - <35.0 kg/m2 (inclusive). Subjects must meet exactly the inclusion BMI at screening, or be screen failed. Subjects who meet the BMI requirement at screening and present at run-in with a BMI of <27.0 or >35 kg/m2

2017 Clinical Trials

134. Targeted Enteral Nutrient Delivery: A Prospective Randomized Study

with spermacide (by male partner), intrauterine device, sponge, spermacide, Norplant®, Depo-Provera® or oral contraceptives. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its identifier (NCT number): NCT03064347 Locations Layout table for location information United States, California USC

2017 Clinical Trials

135. Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

if consistently employed as the patient's preferred and usual lifestyle , sex only with person of the same sex, sex only with vasectomised partner, medroxyprogesterone injections [e.g., Depo-Provera], levonorgestrel intrauterine system [e.g., Mirena], intrauterine device (IUD), or barrier method [e.g., condom, diaphragm] for the duration of the study and for 6 months after the last dose of CT7001. The drug-drug interactions of CT7001 are not fully characterised so contraceptives that are prone to drug-drug

2017 Clinical Trials

136. A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Patients With Rosacea

ring (NuvaRing®), Depo-Provera® (Medroxy progesterone acetate), double barrier methods (e.g., condom and spermicide), or intrauterine device; Female subjects of child bearing potential had to have a negative urine pregnancy test at baseline; Subjects who used make-up had to have used the same brands/types of make-up for a minimum period of 14 days prior to study entry and had to agree to use the same make-up, brand/type, or frequency of use, throughout the study. Exclusion Criteria: Pregnant

2017 Clinical Trials

137. Bionic Pancreas in Children With Hyperinsulinism and Post-Pancreatectomy Diabetes

with subcutaneous insulin by pump at the time of recruitment. Prescription medication regimen stable for > 1 month (except for medications that will not affect the safety of the study and are not expected to affect any outcome of the study, in the judgment of the site PI). Females > 11 years of age must have a negative urine/serum pregnancy test and must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive

2017 Clinical Trials

138. Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis

be able to read, comprehend, and write at a level sufficient to complete study related materials. Female subjects: Women of childbearing potential (WOCBP) must use an effective form of birth control (confirmed by the Investigator). Effective forms of birth control include: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective Intra-uterine device (IUD) intrauterine device/ levonogestrel Intrauterine system (IUS), Depo-Provera(tm

2017 Clinical Trials

139. OT-58 as an Enzyme Replacement Therapy for Patients With Cystathionine Beta-Synthase Deficient Homocystinuria (CBSDH)

investigational product or investigational medical device within 30 days prior to Screening, or while on study Use or planned use of any injectable drugs containing PEG including medroxyprogesterone (e.g. Depo-Provera) injection within 3 months prior to Screening and while on study Known hypersensitivity to PEG-containing product or any components of OT-58 A positive test for HIV antibody, hepatitis B surface antigen, or hepatitis C antibody A history of organ transplantation, chronic immunosuppressive

2017 Clinical Trials

140. Contraceptive use among lactating women in Ganta-Afeshum District, Eastern Tigray, Northern Ethiopia, 2015: a cross sectional study. (PubMed)

delivery was 96.5%. The mode of delivery of the participants was spontaneous, instrumental and caesarean section, 95.5%, 2.0%, and 2.5%, respectively. The magnitude of modern contraceptive (MC) utilization was 68.1% (95% CI: 64.4-71.8). The contraceptive method mix was dominated by Depo-Provera (58.8%) followed by implants (31.8%). Almost all the study participants had at least one antenatal care (ANC) visit (99.7%) during the pregnancy of their index child. Participants who had radio and those who

Full Text available with Trip Pro

2017 BMC Pregnancy and Childbirth

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>